ASPEN: Comparing Zanubrutinib With Ibrutinib in Waldenström Macroglobulinemia – ASH Clinical News
ASPEN: Comparing Zanubrutinib With Ibrutinib in Waldenström Macroglobulinemia – On Location, Other Meetings – ASH Clinical News
ASPEN: Comparing Zanubrutinib With Ibrutinib in Waldenström Macroglobulinemia – On Location, Other Meetings – ASH Clinical News
Lara C. Pullen, PhD, is a freelance medical writer in Chicago, Illinois. New research supports the incorporation of white blood cell (WBC) count into polycythemia…
ASH Academy on Demand is a key resource provided by the American Society of Hematology (ASH) to support members’ continuous education needs and professional development.…
ASH Academy on Demand is a key resource provided by the American Society of Hematology (ASH) to support members’ continuous education needs and professional development.…
ASH Clinical News Editor-in-Chief Aaron Gerds, MD, previews the upcoming May issue of the magazine. Highlights include a feature on the practice of “bagging”…
Naseema Gangat, MBBS, is a professor of medicine in the Division of Hematology at Mayo Clinic in Rochester, Minnesota. In the last two decades, open-access…
Leah Lawrence is a freelance health writer and editor based in Delaware. Use of the direct oral anticoagulant (DOAC) apixaban was not superior to cardiac…
Mary Ellen Schneider is a medical journalist based in Setauket, New York. Ruemu E. Birhiray, MD, is a hematologist/oncologist and clinical investigator at Hematology Oncology…
Katie Robinson is a medical writer based in New York. Compared with placebo, a high dose of oral vitamin A given before a hematopoietic cell…
The U.S. Food and Drug Administration (FDA) accepted Pfizer’s Biologics License Application for marstacimab as treatment for hemophilia A or hemophilia B in patients without…
In the December 2023 issue of “You Make the Call,” Shruti Chaturvedi, MBBS, MS, discussed treatment options for a female patient presenting with a left…